TABLE 3.
Hazard Ratios for Overall Survival by Subgroup
| Subgroup | Number | Adjusted HRa | 95% CI | P Value |
|---|---|---|---|---|
| Age under 65 years | ||||
| Doublets | 449 | 1.0 [Ref] | – | – |
| Pem-based | 123 | 0.84 | 0.67-1.07 | 0.157 |
| Pem + Bev-based | 26 | 0.36 | 0.21-0.64 | < 0.001 |
| Bev-based | 82 | 0.87 | 0.67-1.15 | 0.329 |
| Singlets | 21 | 1.85 | 1.17-2.92 | 0.009 |
| TKI | 131 | 0.76 | 0.59-0.97 | 0.030 |
| Age 65 years and older | ||||
| Doublets | 639 | 1.0 [Ref] | – | – |
| Pem-based | 156 | 1.07 | 0.88-1.30 | 0.475 |
| Pem + Bev-based | 12 | 0.83 | 0.44-1.55 | 0.550 |
| Bev-based | 85 | 1.05 | 0.82-1.34 | 0.705 |
| Singlets | 93 | 1.51 | 1.20-1.90 | < 0.001 |
| TKI | 264 | 0.91 | 0.76-1.08 | 0.265 |
| Nonsquamous histology | ||||
| Doublets | 816 | 1.0 [Ref] | – | – |
| Pem-based | 277 | 0.95 | 0.81-1.10 | 0.468 |
| Pern + Bev-based | 37 | 0.47 | 0.30-0.72 | < 0.001 |
| Bev-based | 163 | 0.95 | 0.79-1.15 | 0.603 |
| Singlets | 95 | 1.40 | 1.11-1.75 | 0.004 |
| TKI | 379 | 0.83 | 0.72-0.96 | 0.013 |
aAdjusted for age, sex, race, region, stage, histology, Charlson Comorbidity Index, smoking, and subsequent therapy.
Bev = bevacizumab; CI = confidence interval; HR = hazard ratio; Pem = pemetrexed; Ref = reference group; TKI = tyrosine-kinase inhibitor.